The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Elective Major Knee Surgery
Open accessAbstract
BACKGROUND: Despite thromboprophylaxis, major knee surgery carries a high risk of venous thromboembolism. Fondaparinux, the first of a new class of synthetic antithrombotic agents, may reduce this risk. METHODS: In a double-blind study, we randomly assigned 1049 consecutive patients undergoing elective major knee surgery to receive subcutaneous doses of either 2.5 mg of fondaparinux once daily or 30 mg of enoxaparin twice daily, with both treatments initiated postoperatively. The primary efficacy outcome was venous thromboembolism up to postoperative day 11, defined as deep-vein thrombosis detected by mandatory bilateral venography, documented symptomatic deep-vein thrombosis, or documented symptomatic pulmonary embolism. The primary safety outcome was major bleeding. RESULTS: The primary efficacy outcome was assessed in 724 patients. The fondaparinux group had a significantly lower incidence of venous thromboembolism by day 11 (12.5 percent [45 of 361 patients]) than the enoxaparin group (27.8 percent [101 of 363 patients]; reduction in risk, 55.2 percent; 95 percent confidence interval, 36.2 to 70.2; P<0.001). Major bleeding (including overt bleeding with a bleeding index of 2 or more) occurred more frequently in the fondaparinux group (P=0.006), but there were no significant differences between the two groups in the incidence of bleeding leading to death or reoperation or occurring in a critical organ. CONCLUSIONS: In patients undergoing elective major knee surgery, postoperative treatment with 2.5 mg of fondaparinux once daily was significantly more effective in preventing deep-vein thrombosis than 30 mg of enoxaparin twice daily.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Venous Thromboembolism
Geerts, W. H., Heit, J. A., Clagett, G. P., Pineo, G. F., Colwell, C. W., Anderson, F. A., & Wheeler, H. B. (2001) · Chest · doi:10.1378/chest.119.1_suppl.132s · Cited by 4,373
Roentgen Diagnosis of Venous Thrombosis in the Leg
Rabinov, K. (1972) · Archives of Surgery · doi:10.1001/archsurg.1972.04180020014004 · Cited by 740
Eriksson, B. I., Bauer, K. A., Lassen, M. R., & Turpie, A. G. G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011100 · Cited by 631
Self-citationThe Unique Antithrombin III Binding Domain of Heparin: A Lead to New Synthetic Antithrombotics
van Boeckel, C. A. A., & Petitou, M. (1993) · Angewandte Chemie International Edition in English · doi:10.1002/anie.199316713 · Cited by 382
A Synthetic Pentasaccharide for the Prevention of Deep-Vein Thrombosis after Total Hip Replacement
Turpie, A. G. G., Gallus, A. S., & Hoek, J. A. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103013440901 · Cited by 380
Self-citation(1990) · JAMA · doi:10.1001/jama.263.20.2753 · Cited by 376
Nicolaides, A. N., Breddin, H. K., Fareed, J., Goldhaber, S. Z., Haas, S., Hull, R., Kalodiki, E., Myers, K. V., Samama, M. M., & Sasahara, A. (2001) · PubMed · Cited by 263
Hull, R. D. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.14.2199 · Cited by 262
Leclerc, J. R., Geerts, W. H., Desjardins, L., Laflamme, G. H., l'Esperance, B., Demers, C., Kassis, J., Cruickshank, M., Whitman, L., & Delorme, F. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-7-199604010-00001 · Cited by 233
Cited by
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Self-citationPrevention of Venous Thromboembolism
Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R., & Colwell, C. W. (2008) · Chest · doi:10.1378/chest.08-0656 · Cited by 3,829
Self-citationKahn (2012) · doi:10.1378/chest.11-2296 · Cited by 2,693
Prevention of VTE in Orthopedic Surgery Patients
Falck-Ytter, Y., Francis, C. W., Johanson, N. A., Curley, C., Dahl, O. E., Schulman, S., Ortel, T. L., Pauker, S. G., & Colwell, C. W. (2012) · Chest · doi:10.1378/chest.11-2404 · Cited by 1,930
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty
Lassen, M. R., Ageno, W., Borris, L. C., Lieberman, J. R., Rosencher, N., Bandel, T. J., Misselwitz, F., & Turpie, A. G. G. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa076016 · Cited by 1,295
Self-citationTurpie, A. G., Lassen, M. R., Davidson, B. L., Bauer, K. A., Gent, M., Kwong, L. M., Cushner, F. D., Lotke, P. A., Berkowitz, S. D., Bandel, T. J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60734-0 · Cited by 981
Self-citationHeparin and Low-Molecular-Weight Heparin
Hirsh, J., & Raschke, R. (2004) · Chest · doi:10.1378/chest.126.3_suppl.188s · Cited by 971
Turpie, A. G. G. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.16.1833 · Cited by 736
Self-citationRogers, F. B., Cipolle, M. D., Velmahos, G., Rozycki, G., & Luchette, F. A. (2002) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/00005373-200207000-00032 · Cited by 713
KUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.011 · Cited by 649
Anderson, D. R., Morgano, G. P., Bennett, C., Dentali, F., Francis, C. W., Garcia, D. A., Kahn, S. R., Rahman, M., Rajasekhar, A., Rogers, F. B., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000975 · Cited by 626
Turpie, A. G., Bauer, K. A., Eriksson, B. I., & Lassen, M. R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08648-8 · Cited by 537
Self-citationThe Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Hirsh, J., Guyatt, G., Albers, G. W., & Schünemann, H. J. (2004) · Chest · doi:10.1378/chest.126.3_suppl.172s · Cited by 411
Relationship Between Deep Venous Thrombosis and the Postthrombotic Syndrome
Kahn, S. R., & Ginsberg, J. S. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.1.17 · Cited by 405
Goldhaber, S. Z. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16004-2 · Cited by 348
Agnelli, G., Bergqvist, D., Cohen, A. T., Gallus, A. S., & Gent, M. (2005) · British Journal of Surgery · doi:10.1002/bjs.5154 · Cited by 337
Francis, C. W., Berkowitz, S. D., Comp, P. C., Lieberman, J. R., Ginsberg, J. S., Paiement, G., Peters, G. R., Roth, A. W., McElhattan, J., & Colwell, C. W. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035162 · Cited by 321
Bijsterveld, N. R., Moons, A. H., Boekholdt, S. M., van Aken, B. E., Fennema, H., Peters, R. J. G., Meijers, J. C. M., Büller, H. R., & Levi, M. (2002) · Circulation · doi:10.1161/01.cir.0000038501.87442.02 · Cited by 316
Januel, J.-M., Chen, G., Ruffieux, C., Quan, H., Douketis, J. D., Crowther, M. A., Colin, C., Ghali, W. A., Burnand, B., & IMECCHI Group, F. T. (2012) · JAMA · doi:10.1001/jama.2011.2029 · Cited by 311
Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences*1
VILESGONZALEZ, J. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.03.011 · Cited by 305
TURPIE, A. G. G., FISHER, W. D., BAUER, K. A., KWONG, L. M., IRWIN, M. W., KÄLEBO, P., MISSELWITZ, F., & GENT, M. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01602.x · Cited by 302
Self-citationThe discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor
Perzborn, E., Roehrig, S., Straub, A., Kubitza, D., & Misselwitz, F. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3185 · Cited by 297
Carbohydrate-based drugs launched during 2000−2021
Cao, X., Du, X., Jiao, H., An, Q., Chen, R., Fang, P., Wang, J., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.020 · Cited by 267
Steele, K. E., Canner, J., Prokopowicz, G., Verde, F., Beselman, A., Wyse, R., Chen, J., Streiff, M., Magnuson, T., Lidor, A., et al. (2015) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2014.10.003 · Cited by 54
Methodological issues in trials assessing primary prophylaxis of venous thrombo-embolism
Thabut, G., Estellat, C., Boutron, I., Samama, C. M., & Ravaud, P. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi587 · Cited by 11
Metadata
- Authors
- Bauer, K. A., Eriksson, B. I., Lassen, M. R., & Turpie, A. G. G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-11
- Volume
- 345
- Issue
- 18
- Pages
- 1305-1310
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2054169479
- Cited by
- 666
- References
- 15
- FWCI
- 37.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.